Retatrutide

30mg — Research Grade

$159.00CAD

Triple agonist targeting GLP-1, GIP, and Glucagon receptors for next-generation metabolic research. Higher-dose 30mg vial for extended research protocols. Retatrutide is the first triple-action incretin, studied for its powerful effects on appetite regulation, fat oxidation, and energy expenditure — outperforming single and dual agonists in clinical trials.

Third-party HPLC lab tested — 99%+ purity verified

Express 1-3 day delivery — $25 flat rate · Free over $299.00

Payment via Interac e-Transfer

For research use only

SKU: RT30